Clinical trial
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
NCT00595829 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
- Lead sponsor
- Exelixis
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- December 31, 2007
- Completion date
- February 28, 2009
- Enrollment
- 3 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.